Trans-acting aptazyme for conditional gene knockdown in eukaryotic cells

Trans-acting hammerhead ribozyme inherits the advantages of being the smallest and best-characterized RNA-cleaving ribozyme, offering high modularity and the ability to cleave any desired sequence without the aid of any protein, as long as the target sequence contains a cleavage site. However, achieving precise control over the trans-acting hammerhead ribozyme would enable safer and more accurate regulation of gene expression. Herein, we described an intracellular selection of hammerhead aptazyme that contains a theophylline aptamer on stem II based on toxin protein IbsC. Based on the intracellular selection, we obtained three new cis-acting hammerhead aptazymes. Moreover, the corresponding trans-acting aptazymes could be efficiently induced by theophylline to knock down different targeted genes in eukaryotic cells. Notably, the best one, T195, exhibited a ligand-dependent and dosedependent response to theophylline, and the cleavage efficiency could be enhanced by incorporating multiplex aptazymes.

Automated summary

Trans-acting hammerhead ribozyme inherits the advantages of being the smallest and best-characterized RNA-cleaving ribozyme, offering high modularity and the ability to cleave any desired sequence without the aid of any protein, as long as the target sequence contains a cleavage site. Precise control over the trans-acting hammerhead ribozyme has been achieved through intracellular selection of hammerhead aptazyme, leading to the development of new cis-acting hammerhead aptazymes that can efficiently knock down targeted genes in eukaryotic cells through induction by theophylline. The best aptazyme, T195, exhibits a ligand-dependent and dose-dependent response to theophylline, with enhanced cleavage efficiency when multiplex aptazymes are incorporated.